EUVIMEDEUVIMED entdecken
Crossref

Beyond the CBC : Can Novel Markers Predict Recurrence in Chronic Rhinosinusitis With Nasal Polyposis?

Hasan Canakci iD, Hasmet Yazici iD, Salih Yayman iD, Kamil Gokce Tulaci iD, Erhan Arslan iD, Omer Hizli iD

Clinical Otolaryngology · 2025

DOI: 10.1111/coa.70024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Otolaryngology, 2025. Verfasst von Hasan Canakci und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, University Medical Center Balikesir, Balikesir, Turkey. Hauptthemen laut MEDLINE: Sinusitis, Nasal Polyps, Rhinitis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to investigate the potential prognostic value of eosinophil count, eosinophil‐monocyte ratio (EMR), total IgE, systemic immune‐inflammatory index (SII), systemic inflammation response index (SIRI), neutrophil‐lymphocyte ratio (NLR), platelet‐lymphocyte ratio (PLR), and the presence of asthma and acetylsalicylic acid (ASA) sensitivity in predicting postoperative recurrence in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).

Methods

Patients with CRSwNP were divided into two groups based on recurrence within 3 years postoperatively: Group 1 (non‐recurrent) included patients with no signs of recurrence, and Group 2 (recurrent) included those with endoscopic evidence of recurrence. A control group of age‐ and gender‐matched healthy individuals without any history of inflammation and with normal nasal endoscopy findings was also included. Eosinophil, EMR, total IgE, NLR, PLR, SII, SIRI, and the presence of asthma and ASA sensitivity were compared among the groups.

Results

The recurrent NP group had significantly higher median total IgE and PLR compared to the non‐recurrent group ( p = 0.036). Compared to controls, the recurrent NP group had significantly elevated eosinophil, EMR, SII, and SIRI levels ( p < 0.001, p = 0.022, and p = 0.038, respectively). No significant differences in PLR, SII, or SIRI were found between the non‐recurrent and control groups ( p = 1). Multivariate logistic regression identified asthma as an independent predictor of recurrence.

Conclusion

EMR, SII, and SIRI may serve as valuable biomarkers in CRSwNP. Their elevated levels in recurrent cases support their potential role in predicting postoperative recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SinusitisNasal PolypsRhinitisHumansMaleFemaleChronic DiseaseRecurrenceBiomarkersAdultMiddle AgedPrognosisLeukocyte CountRetrospective StudiesCase-Control StudiesImmunoglobulin EEosinophilsPredictive Value of TestsRhinosinusitis

Stichwörter der Autor:innen

biomarkerschronic rhinosinusitisnasal polyposisneutrophilplateletsystemic inflammation

Substanzen

BiomarkersImmunoglobulin E

Autor:innen und Institutionen

  • Department of Otolaryngology, University Medical Center Balikesir, Balikesir, Turkey.
  • Private Clinic, Balikesir, Turkey.
  • Department of Otolaryngology, Etlik City Hospital, Ankara, Turkey.

ORCID-Profile: Hasan Canakci, Hasmet Yazici, Salih Yayman, Kamil Gokce Tulaci, Erhan Arslan, Omer Hizli

Zitieren

APA

Canakci, H., Yazici, H., Yayman, S., Tulaci, K. G., Arslan, E., & Hizli, O. (2025). Beyond the CBC : Can Novel Markers Predict Recurrence in Chronic Rhinosinusitis With Nasal Polyposis?. Clinical Otolaryngology. https://doi.org/10.1111/coa.70024

Vancouver

Canakci H, Yazici H, Yayman S, Tulaci KG, Arslan E, Hizli O. Beyond the CBC : Can Novel Markers Predict Recurrence in Chronic Rhinosinusitis With Nasal Polyposis?. Clinical Otolaryngology. 2025. doi:10.1111/coa.70024

BibTeX
@article{Canakci2025,
  author = {Canakci, Hasan and Yazici, Hasmet and Yayman, Salih and Tulaci, Kamil Gokce and Arslan, Erhan and Hizli, Omer},
  title = {Beyond the CBC : Can Novel Markers Predict Recurrence in Chronic Rhinosinusitis With Nasal Polyposis?},
  journal = {Clinical Otolaryngology},
  year = {2025},
  doi = {10.1111/coa.70024}
}
Kostenlos starten →